Orforglipron Capsules

Orforglipron (development code LY3502970; also referred to in the literature as OWL833) is a non-peptide, orally bioavailable small-molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R). It was discovered at Chugai Pharmaceutical and is being developed by Eli Lilly and Company. The molecule has an empirical formula of C37H45F2N9O4, a molecular weight of approximately 717.82 g/mol, and CAS registry number 2212020-52-3. Unlike the peptide GLP-1R agonists (semaglutide, liraglutide, exenatide) that dominated the class historically, orforglipron does not contain an amino acid backbone and is not degraded by dipeptidyl peptidase-4 (DPP-4) or gastrointestinal proteases — the property that makes an oral capsule format practical without permeation enhancers such as the SNAC excipient required for oral semaglutide.

The compound entered clinical development around 2019 and has since been studied in phase 1 and phase 2 trials for type 2 diabetes and obesity. Phase 2 data published in The Lancet and The New England Journal of Medicine in 2023 reported dose-dependent reductions in body weight and HbA1c over 26 to 36 weeks. As of 2024–2025, orforglipron is in phase 3 development (the ACHIEVE and ATTAIN programs) covering type 2 diabetes and obesity indications. If approved, it would be the first non-peptide oral GLP-1R agonist, distinct from oral semaglutide, which is a peptide reformulated with an absorption enhancer.

The differentiator most cited in the medicinal-chemistry literature is biased agonism: orforglipron is reported to preferentially activate Gαs-mediated cAMP signaling at the GLP-1R with reduced β-arrestin recruitment relative to the endogenous GLP-1(7-36) peptide. Whether this pharmacology translates into a distinct clinical profile — for example, differences in tolerability or receptor desensitization — remains an open question that phase 3 readouts and mechanistic follow-up work will need to resolve. It is a proposed advantage, not an established one.

For research use, orforglipron is of interest because it allows investigators to study GLP-1R activation in models where oral administration, formulation with food, and small-molecule pharmacokinetics are relevant experimental variables — parameters that peptide agonists cannot address.

Orforglipron is a small-molecule agonist that binds the glucagon-like peptide-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed on pancreatic β-cells, enteric and central neurons, and other tissues. Its mechanism differs from peptide GLP-1R agonists in binding mode, signaling bias, and pharmacokinetics.

Binding site and structural pharmacology. Cryo-EM structures of the orforglipron–GLP-1R–Gs complex reported by Kawai and colleagues (2020) show that orforglipron occupies a pocket that overlaps only partially with the orthosteric peptide-binding site. The small molecule engages the transmembrane bundle and extracellular loop 2 (ECL2) rather than making the extensive extracellular domain (ECD) contacts characteristic of the native GLP-1 peptide. This distinct engagement is the structural basis for the reported signaling bias.

Downstream signaling. Activation of GLP-1R by orforglipron couples to Gαs, stimulating adenylate cyclase and raising intracellular cAMP. In pancreatic β-cells, cAMP elevation potentiates glucose-stimulated insulin secretion via PKA- and Epac2-dependent pathways. Suppression of glucagon secretion from α-cells and slowing of gastric emptying are additional downstream effects consistent with GLP-1R agonism, though the relative magnitude of each with orforglipron versus peptide agonists has not been fully characterized in humans.

Biased signaling. Preclinical assays report that orforglipron produces cAMP accumulation comparable to native GLP-1 while recruiting β-arrestin less efficiently. Reduced β-arrestin coupling has been proposed to limit receptor internalization and desensitization, which some investigators hypothesize could sustain signaling at the plasma membrane. It should be emphasized that whether this in vitro bias translates into a clinically meaningful difference in efficacy, tolerability, or tachyphylaxis has not been demonstrated — the phase 2 clinical profile so far resembles that of peptide GLP-1R agonists in both benefits and gastrointestinal adverse events.

Pharmacokinetics relevant to oral dosing. Orforglipron is not a peptide and is not subject to proteolytic degradation in the gut. Reported human pharmacokinetics show absorption compatible with once-daily oral dosing and a half-life sufficient to sustain plasma exposure over 24 hours. Unlike oral semaglutide, orforglipron does not require the SNAC absorption enhancer and, in the phase 2 studies, was administered without the strict fasting-and-water restrictions imposed by that formulation. Food effects on absorption have been reported and are under further characterization in phase 3.

Comparison to related compounds. Peptide agonists (semaglutide, liraglutide) require subcutaneous injection or, in the case of oral semaglutide, a specialized formulation and fasted dosing. Dual and triple agonists (tirzepatide, retatrutide) add GIP and/or glucagon receptor activity. Orforglipron is a selective GLP-1R agonist — it does not engage GIP or glucagon receptors — so mechanistic comparisons to multi-receptor agonists should be interpreted with that selectivity in mind.

The distinction that matters most in this table is the entry for compound class. Orforglipron is not a peptide. It does not have a sequence, cannot be represented in single-letter amino acid notation, and is not synthesized by solid-phase peptide synthesis. It is a small organic molecule with a defined structure discoverable through PubChem (CID 145997657). This is what makes oral administration viable without absorption enhancers: the molecule is not subject to proteolytic degradation in the gastrointestinal tract.

Storage of orforglipron capsules (research grade):

• Long-term storage: Store sealed in the original bottle at controlled room temperature, 15-25°C (59-77°F), protected from light, moisture, and direct heat. Small-molecule oral dosage forms of this chemical class do not require refrigeration under sealed conditions and refrigeration is not recommended, as condensation on removal from cold storage can compromise capsule integrity.
• Short-term / working storage: Room temperature, in a dry environment, with the desiccant (if included) retained in the bottle. Keep the bottle tightly closed between uses to limit exposure to atmospheric moisture.
• Transit conditions: Ambient shipping is acceptable. Because orforglipron is a stable small molecule rather than a peptide, brief thermal excursions during transit do not carry the degradation risk that would apply to a lyophilized peptide.

Stability considerations specific to this compound:

• Orforglipron is a small molecule with fluorine substituents and an aromatic scaffold — chemically stable under standard laboratory storage conditions and not subject to the deamidation, oxidation, or aggregation pathways that limit shelf life of peptide GLP-1 agonists such as semaglutide or liraglutide.
• The capsule matrix itself may be sensitive to humidity. Storage in a low-humidity environment, or with the packaged desiccant retained, is appropriate.
• Do not repackage capsules into non-original containers where light and moisture exclusion cannot be assured.
• Once the bottle is opened, use within the manufacturer-labeled period. In the absence of a labeled in-use period, laboratory best practice is to use within 6-12 months of first opening, provided storage conditions have been maintained.

Handling: Wear gloves when handling capsules for research use. Orforglipron is an investigational compound with no established human safety envelope outside of ongoing clinical trials; incidental exposure is not established as safe. Store separately from consumables and clearly labeled as a research material not intended for human or veterinary use.